Global Scleroderma Treatment Market 2017-2021
- Published: Jun 2017
- Pages: 83
- SKU: IRTNTR13556
Enjoy complimentary customisation on priority with our Enterprise License!
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
This market research study identifies AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Pfizer as the leading players in the global scleroderma treatment market. A comprehensive analysis of this market is also presented by drug class (anti-inflammatory drugs, immunosuppressants, PDE5 inhibitors, calcium channel blockers, and others) and by geography (the Americas, APAC, and EMEA).
Overview of the global scleroderma treatment market
According to Technavio’s market research report, the global scleroderma treatment market will grow at a CAGR of more than 7% during the forecast period. One of the key factors that will stimulate the growth of this market during the forecast period is the increased funding for research and developmental activities. The rising unmet needs of the scleroderma treatment is compelling the government and non-government organizations to invest more in R&D projects that are focused on specific symptoms and features of scleroderma. Scleroderma Research Foundation is one of the organizations that supports leading innovators and scientists in various fields by investing in research projects. Stanford University is already working on a new project that focuses on the comparative study of gender-specific gene regulatory networks in scleroderma patients and healthy volunteers. Such studies help in the identification of the possible source of cancer and autoimmune disorders and will in turn, enable innovators to come up with better scleroderma treatments.
Stem cell transplants can provide sustained remissions in patients with severe autoimmune diseases such as lupus, rheumatoid arthritis, juvenile arthritis, and multiple sclerosis. The autologous blood cell stem cell transplants can significantly improve the survival rate of patients suffering from scleroderma. This will increase the adoption of stem cell therapy for the treatment of scleroderma and according to this industry research report, this will be one of the key trends that will gain traction in the scleroderma treatment market in the coming years.
Competitive landscape and key vendors
The scleroderma treatment market is highly fragmented due to the presence of many key vendors. These vendors are increasingly competing against each other based on factors such as aggressive pricing and new indications. Vendors are taking efforts to address the unmet medical needs by providing novel therapeutics. They are also focusing on the development of drugs in new route of administrations (ROAs) such as topical patches. To improve their market positions, the players in this marketspace also focus on adopting strategies such as M&As and distribution through partnerships.
Key vendors in this market are -
- AstraZeneca
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Pfizer
Other prominent vendors in the market include Amgen, Bayer AG, Boehringer Ingelheim, Biogen, CELGENE, Corbus Pharmaceuticals, Johnson & Johnson, Merck, Novartis, and Sanofi.
Segmentation by drug class and analysis of the scleroderma treatment market
- Anti-inflammatory drugs
- Immunosuppressants
- PDE5 inhibitors
- Calcium channel blockers
Inflammations in patients who are suffering from scleroderma are treated with anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. The conventional type of inflammation causes myositis (inflammation in the muscles), serositis (inflammation of the serous membrane), and arthritis (inflammation in the joints). Owing to the increasing number of patient assistance programs, the anti-inflammatory drugs segment accounted for the major shares of the market during 2016. Analysts predict that this segment will continue to contribute for the maximum market shares during the next four years as well and this will attribute to the rising demand for prednisone and ibuprofen.
Segmentation by geography and analysis of the scleroderma treatment market
- Americas
- APAC
- EMEA
With the high prevalence rate of scleroderma in countries such as the US, the Americas accounted for the majority market share during 2016. The availability of the treatment for scleroderma will increase during the forecast period due to the increasing investments from the government towards R&D activities for rare diseases. Additionally, several government and non-government organizations in this region are also taking initiatives to support scleroderma patients.
Key questions answered in the report include
- What will the market size and the growth rate be in 2021?
- What are the key factors driving the global scleroderma treatment market?
- What are the key market trends impacting the growth of the global scleroderma treatment market?
- What are the challenges to market growth?
- Who are the key vendors in the global scleroderma treatment market?
- What are the market opportunities and threats faced by the vendors in the global scleroderma treatment market?
- What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
- What are the key outcomes of the five forces analysis of the global scleroderma treatment market?
Technavio also offers customization on reports based on specific client requirement
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
- Market outline
- Scleroderma disease overview
- Market landscape
- Market overview
- Five forces analysis
PART 05: Pipeline landscape
PART 06: Market segmentation by drug class
- Anti-inflammatory drugs
- Immunosuppressants
- Others
- PDE5 inhibitors
- Calcium channel blockers
PART 07: Geographical segmentation
- Scleroderma treatment market in Americas
- Scleroderma treatment market in EMEA
- Scleroderma treatment market in APAC
PART 08: Decision framework
PART 09: Drivers and challenges
- Market drivers
- Market challenges
PART 10: Market trends
- Partnerships and strategic alliances
- Introduction of stem cells in scleroderma treatment
- Advent of novel therapies
PART 11: Vendor landscape
- Competitive scenario
PART 12: Key vendor analysis
- AstraZeneca
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Pfizer
- Other prominent vendors
PART 13: Appendix
- List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases

DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts

REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
Certified ISO 9001 : 2015

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
2500 USD
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
- Our analysts will work directly with you and understand your needs
- Get data on specified regions or segments, competitor and Vendors
- Data will be formatted and presented as per your requirements
- We offer $1000 worth of FREE customization at the time of purchase
Let us help you make report more suited to your requirements.
- Get a competitive breakdown as per your niche industry
- Customize the data with various metrics that meet your business prerequisite
- Understand Revenue Sources, Customers and many more
- Details on Market Share
- These customizations are done in a short amount of time by our analysts and industry experts
